Microvast Holdings announces departure of chief financial officer
Investing.com - Adverum Biotechn reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Adverum Biotechn announced earnings per share of $-0.400 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.350 on revenue of $0.
Adverum Biotechn 's are down 53.92% and is trading at $0.732 , still down 67.96% from its 52 week high of $2.29 set on Thursday, November 11, 2021.
Adverum Biotechn follows other major Healthcare sector earnings this month
Adverum Biotechn's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar